CD8 T cell receptor complex (TCR–CD8 complex)

The CD8 T cell receptor complex is present on cytotoxic CD8+ T lymphocytes, comprising the highly variable T-cell receptor (TCR, usually αβ heterodimers), the CD8 co-receptor (either as a CD8αα homodimer or CD8αβ heterodimer), and the signaling CD3 subunits. The TCR recognizes antigenic peptides presented by MHC class I on target cells, while CD8 stabilizes the interaction by binding to the non-variable region of the MHC-I molecule. The cytoplasmic tail of CD8 recruits Lck kinase, facilitating signal transduction upon antigen recognition and promoting T cell activation, proliferation, and effector function. This complex is a principal mediator of immune responses against infected, malignant, or otherwise aberrant cells, and is a prominent focus of immunotherapy, diagnostic, and biomarker strategies. Structural diversity and variable expression of CD8 and TCR allow for precise and tailored immune recognition; targeted monoclonal antibodies and engineered T cell therapies leverage these properties for therapeutic benefit. If more precise molecular definition is required (e.g., UniProt, gene names), constituent proteins include: - T-cell receptor alpha and beta chains (TCRα, TCRβ) - CD8 alpha and beta chains (CD8α, CD8β) - CD3 subunits (CD3ε, CD3δ, CD3γ, CD3ζ) In summary, the CD8 T cell receptor complex is a canonical immunological receptor complex critical for adaptive immune defense and represents an established, multifaceted therapeutic and biomarker target.

Other names

CD8+ T cell receptor complexCD8 TCR complexCytotoxic T lymphocyte receptor complexTCR–CD8 complex

Antibody-induced depletion or functional modulation of CD8+ T cells Enhanced TCR signaling and antigen recognition (via engineered CAR mimicking CD8 function)